Padcev Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of urothelial cancer, limitations of conventional chemotherapy, advancements in monoclonal antibody engineering, expansion of oncology clinical trials, regulatory approvals for novel cancer drugs.

The growth in the forecast period can be attributed to expansion of adc-based oncology pipelines, increasing investment in targeted cancer therapies, rising adoption of personalized oncology treatments, growing integration of companion diagnostics, advancement of combination cancer therapy approaches. Major trends in the forecast period include increasing adoption of antibody-drug conjugate therapies, rising use of targeted oncology treatments, expansion of precision cancer therapeutics, growing focus on biomarker-driven drug development, enhanced oncology manufacturing capabilities.

The increasing incidence of bladder cancer is expected to drive the growth of the Padcev market moving forward. Bladder cancer is characterized by the abnormal growth of cells in the bladder, which can lead to tumors and disrupt normal urinary function. The rise in bladder cancer cases is attributed to factors such as smoking, exposure to industrial chemicals, chronic bladder infections, and a family history of the disease. Padcev aids in the treatment of bladder cancer by targeting a specific protein on cancer cells and delivering a chemotherapy drug directly to the tumor, which helps destroy the cancer cells and improve patient outcomes in the advanced stages of the disease. For example, in March 2024, the American Cancer Society's Facts and Figures reported an estimated 83,190 new cases of urinary bladder cancer in 2024, showing a slight increase from 82,290 new cases in 2023. As a result, the rising incidence of bladder cancer is fueling the growth of the Padcev market.

A key trend in the Padcev market is the development of innovative therapies, such as combination therapy, to improve treatment efficacy and enhance patient outcomes in cancer care. Combination therapy involves using two or more treatments or drugs together to target a specific condition, thereby enhancing the overall therapeutic effect. For instance, in August 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from the European Commission for PADCEV (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA (pembrolizumab, a PD-1 inhibitor). This combination therapy is used to treat advanced urothelial cancer, leveraging enfortumab vedotin's targeted therapy alongside KEYTRUDA's immune checkpoint inhibition to enhance anti-cancer efficacy.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition significantly expands Pfizer's oncology portfolio by incorporating Seagen's innovative cancer therapies, including four commercial drugs - Adcetris, Padcev, Tukysa, and Tivdak. Seagen Inc. is a US-based biotechnology company specializing in innovative cancer treatments, including PADCEV (enfortumab vedotin).

Major companies operating in the padcev market are Astellas Pharma Inc.

North America was the largest region in the padcev market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the padcev market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the padcev market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the padcev market by increasing costs of imported biologic drug components, cytotoxic payload materials, specialized manufacturing equipment, and sterile injectable packaging systems. Oncology drug production hubs in North America and Europe are particularly affected due to reliance on cross-border sourcing of high-value pharmaceutical inputs. These tariffs can contribute to higher treatment costs and supply chain complexity for cancer therapies. However, they are also driving increased domestic manufacturing investments, regional contract development partnerships, and long-term resilience in oncology drug supply chains.

The padcev market research report is one of a series of new reports that provides padcev market statistics, including padcev industry global market size, regional shares, competitors with a padcev market share, detailed padcev market segments, market trends and opportunities, and any further data you may need to thrive in the padcev industry. This padcev market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Padcev (enfortumab vedotin) is a medication used to treat certain types of cancer, specifically metastatic urothelial carcinoma, a form of bladder cancer. It is an antibody-drug conjugate (ADC) that combines a targeted antibody with a chemotherapy drug. The antibody specifically targets and binds to the Nectin-4 protein, found on the surface of cancer cells. Once bound, the chemotherapy drug is released into the cancer cell, leading to its destruction. Padcev is typically used in patients who have previously received treatments, including chemotherapy or immune checkpoint inhibitors.

The main clinical indications for Padcev include urothelial cancer and bladder cancer. Urothelial cancer, which is the most common form of bladder cancer, is effectively treated with Padcev, a targeted therapy that targets specific proteins in cancer cells. It is distributed through various channels, such as retail pharmacies and online pharmacies, and is used by a wide range of end users, including hospitals, clinics, ambulatory care centers, and home care providers.

The padcev market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.